Kamada Ltd. (KMDA) Aandelenanalyse

Bedrijfsoverzicht

Kamada Ltd. is a specialized manufacturer and distributor of plasma-derived protein therapeutics designed for specific medical prophylaxis needs. The company operates within the Healthcare sector, specifically classified under the Drug Manufacturers - Specialty & Generic industry, which focuses on producing niche pharmaceutical products rather than mass-market medications. As of the latest data, the entity manages a market capitalization of $490.86M while generating total annual revenue of $180.46M with a workforce of 462 employees. These valuation and revenue figures indicate that Kamada Ltd. occupies a mid-cap position in the specialty pharmaceutical space, suggesting a company with established production capabilities but one that has not yet reached the scale of large-cap biopharmaceutical giants.

Financiële gezondheid

The company reported a revenue of $180.46M and a net income of $20.20M over the trailing twelve months, resulting in an EBITDA of $39.51M. The significant gap between the $180.46M in revenue and the $20.20M in net income reveals a cost structure where operating expenses, including cost of goods sold and administrative costs, consume a substantial portion of top-line sales before arriving at the bottom line. Kamada Ltd. generated $7.59M in free cash flow, which provides the organization with financial flexibility to fund ongoing research, development, or routine capital expenditures without needing to immediately seek external financing. The company maintains a conservative balance sheet with $75.47M in cash against $11.56M in debt, a stark disparity highlighted by a debt-to-equity ratio of 4.30. This liquidity position, further supported by a current ratio of 4.07, indicates strong short-term liquidity and the ability to comfortably meet obligations due within one year. Regarding return metrics, the Return on Equity stands at 7.6% while the Return on Assets is 4.4%, figures that reveal the effectiveness of management in utilizing shareholder capital and total assets to generate profits.

Waarderingsbeoordeling

Kamada Ltd. trades with a trailing P/E ratio of 24.26 and a forward P/E of 14.31, implying that the market expects a significant expansion in earnings per share to justify the lower forward multiple. The price-to-book ratio is 1.82, indicating that the stock is trading at a premium relative to its tangible book value, likely reflecting intangible assets or growth expectations inherent in the specialty drug sector. Alternative valuation metrics such as a price-to-sales ratio of 2.72 and an EV/EBITDA of 10.78 suggest the market values the company based on its sales efficiency and earnings power relative to enterprise value. The stock has traded between a 52-week low of $6.15 and a 52-week high of $9.35, meaning the current price sits within this historical range relative to the volatility observed over the past year. With a beta of 0.31, the company exhibits low price volatility relative to the broader market, suggesting its share price is less sensitive to general market fluctuations compared to high-beta equities.

Growth & Income

Revenue growth for the trailing twelve months stands at 14.5%, while earnings growth registered at -14.1%, indicating that earnings are currently growing slower than revenue or contracting while top-line sales expand. This divergence suggests that the company is facing margin compression or one-time costs that are impacting profitability despite positive sales momentum. As a non-dividend payer with a dividend yield of 2.9% and a payout ratio of 0.0%, the company reinvests its earnings back into the business rather than distributing cash to shareholders. Consequently, the overall growth and income profile is characterized by capital appreciation potential driven by revenue expansion and internal reinvestment, rather than current income generation through dividends.